IRIS Accounts Production v26.1.10.61 02431462 Board of Directors 1.3.25 28.2.26 28.2.26 8/7/2026 false true false false false true false Auditors Opinion iso4217:GBP iso4217:USD iso4217:EUR xbrli:shares xbrli:pure utr:tonnes utr:kWh 02431462 2025-02-28 02431462 2026-02-28 02431462 2025-03-01 2026-02-28 02431462 2024-02-29 02431462 2024-03-01 2025-02-28 02431462 2025-02-28 02431462 ns15:EnglandWales 2025-03-01 2026-02-28 02431462 ns14:PoundSterling 2025-03-01 2026-02-28 02431462 ns10:Director1 2025-03-01 2026-02-28 02431462 ns10:PrivateLimitedCompanyLtd 2025-03-01 2026-02-28 02431462 ns10:SmallEntities 2025-03-01 2026-02-28 02431462 ns10:Audited 2025-03-01 2026-02-28 02431462 ns10:SmallCompaniesRegimeForDirectorsReport 2025-03-01 2026-02-28 02431462 ns10:SmallCompaniesRegimeForAccounts 2025-03-01 2026-02-28 02431462 ns10:FullAccounts 2025-03-01 2026-02-28 02431462 1 2025-03-01 2026-02-28 02431462 ns10:Director2 2025-03-01 2026-02-28 02431462 ns10:RegisteredOffice 2025-03-01 2026-02-28 02431462 ns5:CurrentFinancialInstruments 2026-02-28 02431462 ns5:CurrentFinancialInstruments 2025-02-28 02431462 ns5:ShareCapital 2026-02-28 02431462 ns5:ShareCapital 2025-02-28 02431462 ns5:RetainedEarningsAccumulatedLosses 2026-02-28 02431462 ns5:RetainedEarningsAccumulatedLosses 2025-02-28 02431462 ns5:IntangibleAssetsOtherThanGoodwill 2025-03-01 2026-02-28 02431462 ns5:PatentsTrademarksLicencesConcessionsSimilar 2025-03-01 2026-02-28 02431462 ns5:PlantMachinery 2025-03-01 2026-02-28 02431462 ns5:IntangibleAssetsOtherThanGoodwill 2025-02-28 02431462 ns5:IntangibleAssetsOtherThanGoodwill 2026-02-28 02431462 ns5:IntangibleAssetsOtherThanGoodwill 2025-02-28 02431462 ns5:PlantMachinery 2025-02-28 02431462 ns5:PlantMachinery 2026-02-28 02431462 ns5:PlantMachinery 2025-02-28 02431462 ns5:WithinOneYear ns5:CurrentFinancialInstruments 2026-02-28 02431462 ns5:WithinOneYear ns5:CurrentFinancialInstruments 2025-02-28

REGISTERED NUMBER: 02431462 (England and Wales)

Financial Statements for the Year Ended 28 February 2026

for

Bio-Logic Science Instruments Ltd

| Bio-Logic Science Instruments Ltd (Registered number: 02431462) |

Contents of the Financial Statements

for the Year Ended 28 February 2026

Page |

| Company Information | 1 |

| Balance Sheet | 2 |

| Notes to the Financial Statements | 3 |

| Bio-Logic Science Instruments Ltd |

Company Information

for the Year Ended 28 February 2026

| DIRECTORS: | Mr J Griffiths

| Mr F G Goy

| REGISTERED OFFICE: | Bradbury House

| Market Street

| Glossop

| Derbyshire

| SK13 8AR

| REGISTERED NUMBER: | 02431462 (England and Wales)

| AUDITORS: | SMH Group Audit

| Statutory Auditors

| 5 Westbrook Court

| Sharrow Vale Road

| Sheffield

| South Yorkshire

| S11 8YZ

| Bio-Logic Science Instruments Ltd (Registered number: 02431462) |

Balance Sheet

28 February 2026

| 2026 |  | 2025

| Notes | £ | £ |

FIXED ASSETS

Intangible assets | 4 | - |  | - |  |

Tangible assets | 5 | 27,174 |  | 9,636 |  |

27,174 |  | 9,636 |  |

CURRENT ASSETS

Debtors | 6 | 299,141 |  | 530,515 |  |

Cash at bank | 266,237 |  | 689,257 |  |

565,378 |  | 1,219,772 |  |

CREDITORS

Amounts falling due within one year | 7 | (118,269 | ) | (422,434 | ) |

NET CURRENT ASSETS | 447,109 |  | 797,338 |  |

TOTAL ASSETS LESS CURRENT LIABILITIES | 474,283 |  | 806,974 |  |

PROVISIONS FOR LIABILITIES | (6,794 | ) | (2,435 | ) |

NET ASSETS | 467,489 |  | 804,539 |  |

CAPITAL AND RESERVES

Called up share capital | 300 |  | 300 |  |

Retained earnings | 467,189 |  | 804,239 |  |

SHAREHOLDERS' FUNDS | 467,489 |  | 804,539 |  |

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 3 July 2026 and were signed on its behalf by:

Mr J Griffiths - Director

| Bio-Logic Science Instruments Ltd (Registered number: 02431462) |

Notes to the Financial Statements

for the Year Ended 28 February 2026

1. | STATUTORY INFORMATION

| Bio-Logic Science Instruments Ltd is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

| The presentation currency of the financial statements is the Pound Sterling (£).

2. | ACCOUNTING POLICIES

| Basis of preparing the financial statements

| These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

| Related party exemption

| The company has taken advantage of exemption, under the terms of Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland', not to disclose related party transactions within the group.

| Turnover

| Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

| Revenue from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have transferred to the buyer, usually on despatch of the goods, the amount of revenue can be measured reliably, it is probable that the associated economic benefits will flow to the entity, and the costs incurred or to be incurred in respect of the transactions can be measured reliably. When the outcome of a transaction involving the rendering of services can be reliably estimated, revenue from the rendering of services is measured by reference to the stage of completion of the service transaction at the end of the reporting period.

| When the outcome of a transaction involving the rendering of services cannot be reliably estimated, revenue is recognised only to the extent that expenses recognised are recoverable. The turnover shown in the profit and loss account represents the amounts invoiced during the year, excluding VAT, modified by the inclusion of the value of ongoing contracts. Income from research grants is included in turnover over the life of the research project.

| Intangible assets

| Intangible assets are initially measured at cost. After initial recognition, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

| Patents and licences are being amortised evenly over their estimated useful life of four years.

| Intangible assets are initially measured at cost. After initial recognition, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

| Patents and licenses are fully amortised.

| Bio-Logic Science Instruments Ltd (Registered number: 02431462) |

Notes to the Financial Statements - continued

for the Year Ended 28 February 2026

2. | ACCOUNTING POLICIES - continued

| Tangible fixed assets

| Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

| Plant and machinery etc | - | 33% on reducing balance and 15% on reducing balance

| Tangible assets are initially recorded at cost, and subsequently stated at cost less any accumulated depreciation and impairment losses. Any tangible assets carried at revalued amounts are recorded at the fair value at the date of revaluation less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

| An increase in the carrying amount of an asset as a result of a revaluation, is recognised in other comprehensive income and accumulated in equity, except to the extent it reverses a revaluation decrease of the same asset previously recognised in profit or loss. A decrease in the carrying amount of an asset as a result of revaluation, is recognised in other comprehensive income to the extent of any previously recognised revaluation increase accumulated in equity in respect of that asset. Where a revaluation decrease exceeds the accumulated revaluation gains accumulated in equity in respect of that asset, the excess shall be recognised in profit or loss.

| Asset impairment

| A review for indicators of impairment is carried out at each reporting date, with the recoverable amount being estimated where such indicators exist. Where the carrying value exceeds the recoverable amount, the asset is impaired accordingly. Prior impairments are also reviewed for possible reversal at each reporting date.

| Financial instruments

| A financial asset or a financial liability is recognised only when the entity becomes a party to the contractual provisions of the instrument

| Basic financial instruments are initially recognised at the transaction price, unless the arrangement constitutes a financing transaction, where it is recognised at the present value of the future payments discounted at a market rate of interest for a similar debt instrument. Debt instruments are subsequently measured at amortised cost.

| Other financial instruments, including derivatives, are initially recognised at fair value, unless payment for an asset is deferred beyond normal business terms or financed at a rate of interest that is not a market rate, in which case the asset is measured at the present value of the future payments discounted at a market rate of interest for a similar debt instrument.

| Financial assets that are measured at cost or amortised cost are reviewed for objective evidence of impairment at the end of each reporting date. If there is objective evidence of impairment, an impairment loss is recognised in profit or loss immediately. Any reversals of impairment are recognised in profit or loss immediately, to the extent that the reversal does not result in a carrying amount of the financial asset that exceeds what the carrying amount would have been had the impairment not previously been recognised.

| Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the entity after deducting all of its financial liabilities.

| Where the contractual terms of share capital do not have any terms meeting the definition of a financial liability then this is classed as an equity instrument. Dividends and distributions relating to equity instruments are debited direct to equity.

| Bio-Logic Science Instruments Ltd (Registered number: 02431462) |

Notes to the Financial Statements - continued

for the Year Ended 28 February 2026

2. | ACCOUNTING POLICIES - continued

| Taxation

| Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

| Current or deferred taxation assets and liabilities are not discounted.

| Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

| Deferred tax

| Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

| Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

| Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

| Research and development

| Expenditure on research and development is written off in the year in which it is incurred.

| Foreign currencies

| Foreign currency transactions are initially recorded in the functional currency, by applying the spot exchange rate as at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are translated at the exchange rate ruling at the reporting date, with any gains or losses being taken to the profit and loss account.

| Hire purchase and leasing commitments

| Rentals paid under operating leases are charged to profit or loss on a straight line basis over the period of the lease.

| Pension costs and other post-retirement benefits

| The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

| Provisions

| Provisions are recognised when the entity has an obligation at the reporting date as a result of a past event, it is probable that the entity will be required to transfer economic benefits in settlement and the amount of the obligation can be estimated reliably. Provisions are recognised as a liability in the statement of financial position and the amount of the provision as an expense.

| Provisions are initially measured at the best estimate of the amount required to settle the obligation at the reporting date and subsequently reviewed at each reporting date and adjusted to reflect the current best estimate of the amount that would be required to settle the obligation. Any adjustments to the amounts previously recognised are recognised in profit or loss unless the provision was originally recognised as part of the cost of an asset. When a provision is measured at the present value of the amount expected to be required to settle the obligation, the unwinding of the discount is recognised as a finance cost in profit or loss in the period it arises.

| Short term employee benefits

| Short term employee benefits, including holiday pay, are recognised as an expense in the period in which they are incurred.

| Bio-Logic Science Instruments Ltd (Registered number: 02431462) |

Notes to the Financial Statements - continued

for the Year Ended 28 February 2026

3. | EMPLOYEES AND DIRECTORS

| The average number of employees during the year was 7 (2025 - 8 ) .

4. | INTANGIBLE FIXED ASSETS

| Other

| intangible

| assets

£ |

| COST

| At 1 March 2025

| and 28 February 2026 | 18,750 |  |

| AMORTISATION

| At 1 March 2025

| and 28 February 2026 | 18,750 |  |

| NET BOOK VALUE

| At 28 February 2026 | - |  |

| At 28 February 2025 | - |  |

5. | TANGIBLE FIXED ASSETS

| Plant and

| machinery

| etc

£ |

| COST

| At 1 March 2025 | 36,300 |  |

| Additions | 21,165 |  |

| At 28 February 2026 | 57,465 |  |

| DEPRECIATION

| At 1 March 2025 | 26,664 |  |

| Charge for year | 3,627 |  |

| At 28 February 2026 | 30,291 |  |

| NET BOOK VALUE

| At 28 February 2026 | 27,174 |  |

| At 28 February 2025 | 9,636 |  |

6. | DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR |

2026 | 2025 |

£ | £ |

| Trade debtors | 67,354 |  | 138,884 |  |

| Amounts owed by group undertakings | 195,781 |  | 368,960 |  |

| Other debtors | 36,006 |  | 22,671 |  |

299,141 |  | 530,515 |  |

| Bio-Logic Science Instruments Ltd (Registered number: 02431462) |

Notes to the Financial Statements - continued

for the Year Ended 28 February 2026

7. | CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR |

2026 | 2025 |

£ | £ |

| Trade creditors | 14,403 |  | 19,624 |  |

| Amounts owed to group undertakings | 61,933 |  | 131,381 |  |

| Taxation and social security | 22,389 |  | 208,862 |  |

| Other creditors | 19,544 |  | 62,567 |  |

118,269 |  | 422,434 |  |

8. | DISCLOSURE UNDER SECTION 444(5B) OF THE COMPANIES ACT 2006

| The Report of the Auditors was unqualified.

| James Salim FCCA (Senior Statutory Auditor)

| for and on behalf of SMH Group Audit

9. | ULTIMATE CONTROLLING PARTY

| The immediate parent company is Bio-Logic SAS, a company registered in France.